These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20558730

  • 1. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
    Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.
    J Biol Chem; 2010 Aug 27; 285(35):27251-27258. PubMed ID: 20558730
    [Abstract] [Full Text] [Related]

  • 2. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.
    J Biol Chem; 2009 Apr 03; 284(14):9513-20. PubMed ID: 19164292
    [Abstract] [Full Text] [Related]

  • 3. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
    Young KA, Chen XS, Holers VM, Hannan JP.
    J Biol Chem; 2007 Dec 14; 282(50):36614-25. PubMed ID: 17925391
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM.
    J Immunol; 2001 Nov 15; 167(10):5758-66. PubMed ID: 11698449
    [Abstract] [Full Text] [Related]

  • 6. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
    Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM.
    J Immunol; 2006 Jul 01; 177(1):383-94. PubMed ID: 16785534
    [Abstract] [Full Text] [Related]

  • 7. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.
    Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP.
    J Virol; 2008 Nov 01; 82(22):11217-27. PubMed ID: 18786993
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM.
    Biochemistry; 2001 May 22; 40(20):5931-41. PubMed ID: 11352728
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
    Hannan JP.
    Curr Protein Pept Sci; 2016 May 22; 17(5):463-87. PubMed ID: 26916158
    [Abstract] [Full Text] [Related]

  • 12. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD.
    J Immunol; 2001 Aug 01; 167(3):1490-9. PubMed ID: 11466369
    [Abstract] [Full Text] [Related]

  • 13. Structure of complement receptor 2 in complex with its C3d ligand.
    Szakonyi G, Guthridge JM, Li D, Young K, Holers VM, Chen XS.
    Science; 2001 Jun 01; 292(5522):1725-8. PubMed ID: 11387479
    [Abstract] [Full Text] [Related]

  • 14. The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.
    Henchoz-Lecoanet S, Jeannin P, Aubry JP, Graber P, Bradshaw CG, Pochon S, Bonnefoy JY.
    Immunology; 1996 May 01; 88(1):35-9. PubMed ID: 8707347
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
    Molina H, Perkins SJ, Guthridge J, Gorka J, Kinoshita T, Holers VM.
    J Immunol; 1995 May 15; 154(10):5426-35. PubMed ID: 7730644
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study.
    Gilbert HE, Eaton JT, Hannan JP, Holers VM, Perkins SJ.
    J Mol Biol; 2005 Feb 25; 346(3):859-73. PubMed ID: 15713468
    [Abstract] [Full Text] [Related]

  • 20. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L, Isenman DE.
    J Immunol; 2000 Oct 01; 165(7):3839-48. PubMed ID: 11034390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.